Tandem Diabetes Care Inc (TNDM) FinancialsTNDMTandem Diabetes Care Inc

Tandem Diabetes Care, Inc. (TNDM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pump, accounting for 45.0% of total sales, equivalent to $114.65M. Other significant revenue streams include Supplies and other - Domestic and Supplies and other-International. Understanding this composition is critical for investors evaluating how TNDM navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Tandem Diabetes Care, Inc. maintains a gross margin of 56.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.22%, while the net margin is -8.28%. These profitability ratios, combined with a Return on Equity (ROE) of -48.03%, provide a clear picture of how effectively TNDM converts its operational activities into shareholder value.

In the context of the broader market, TNDM competes directly with industry leaders such as ENOV and IRMD. With a market capitalization of $1.11B, it holds a significant position in the sector. When comparing efficiency, TNDM's gross margin of 56.11% stands against ENOV's 54.51% and IRMD's 74.07%. Such benchmarking helps identify whether Tandem Diabetes Care, Inc. is trading at a premium or discount relative to its financial performance.

Tandem Diabetes reported Q2 2026 revenue of $254.6 million, slightly exceeding expectations, with a gross margin of 56.87%. However, the company has been operating at a net loss, with a net income of -21.17 million in Q2 2026.